福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VRTX 福泰制药

盘后交易 09-01 17:33:35 EDT

547.65

+3.13

+0.57%

盘后549.96

+2.31+0.42%

17:26 EDT

最高551.40	最低545.08	成交量73.43万
今开548.60	昨收544.52	日振幅1.16%
总市值1,389亿	流通市值1,389亿	总股本2.54亿
成交额4.03亿	换手率0.29%	流通股本2.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VRTX","market":"US","secType":"STK","nameCN":"福泰制药","latestPrice":547.65,"timestamp":1788292800000,"preClose":544.52,"halted":0,"volume":734275,"hourTrading":{"tag":"盘后","latestPrice":549.96,"preClose":547.65,"latestTime":"17:26 EDT","volume":21496,"amount":11772280.96064,"timestamp":1788297977302,"change":2.31,"changeRate":0.004218,"amplitude":0.004675},"delay":0,"changeRate":0.005748181884962895,"floatShares":253718831,"shares":253718831,"eps":17.182146,"marketStatus":"盘后交易","change":3.13,"latestTime":"09-01 17:33:35 EDT","open":548.6,"high":551.4,"low":545.08,"amount":402507453.3225,"amplitude":0.011607,"askPrice":551.48,"askSize":56,"bidPrice":548.51,"bidSize":5,"shortable":3,"etf":0,"ttmEps":17.182146,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":544.52,"preHourTrading":{"tag":"盘前","latestPrice":548.69,"preClose":544.52,"latestTime":"09:29 EDT","volume":1560,"amount":848637.66,"timestamp":1788269399999,"change":4.17,"changeRate":0.007658,"amplitude":0.020026},"postHourTrading":{"tag":"盘后","latestPrice":549.96,"preClose":547.65,"latestTime":"17:26 EDT","volume":21496,"amount":11772280.96064,"timestamp":1788297977302,"change":2.31,"changeRate":0.004218,"amplitude":0.004675},"volumeRatio":0.80878,"impliedVol":0.28,"impliedVolPercentile":0.2143},"requestUrl":"/m/hq/s/VRTX","defaultTab":"news","newsList":[{"id":"1187673248","title":"异动解读｜福泰制药盘中上涨3.04%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1187673248","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187673248?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:36","pubTimestamp":1787150201,"startTime":"0","endTime":"0","summary":"8月19日，福泰制药盘中上涨3.04%，报543.95美元/股，成交额1.24亿美元。此外，竞争对手囊性纤维化药物研发未达预期，进一步巩固了公司在该领域的主导地位。基本面方面，公司二季度营收33.34亿美元超市场预期，全年收入指引上调至131亿至132亿美元。多家机构维持买入评级，高盛目标价652美元、Jefferies目标价610美元，均显著高于当前股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192978278","title":"异动解读｜福泰制药盘中上涨3.09%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1192978278","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192978278?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:03","pubTimestamp":1787069031,"startTime":"0","endTime":"0","summary":"8月18日，福泰制药盘中上涨3.09%，报531.475美元/股，成交额2.2亿美元。消息面上，RBC Capital近期发布研报指出，福泰制药拥有多个潜在管线催化剂，整体风险收益比偏正面。此外，此前竞争对手药物研发未达预期，进一步强化了公司在囊性纤维化领域的领先地位。公司二季度营收33.34亿美元超预期，全年收入指引上调至131亿至132亿美元，多家机构维持买入评级，目标价普遍高于当前股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658930620?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","SG9999001176.SGD","LU1069344957.HKD","LU0256863811.USD","BIB","PBE","IE0009355771.USD","IBBQ","BK4139","TBXU","SG9999001176.USD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","BK4585","GNMX","LU2456880835.USD","IE00BJT1NW94.SGD","LU2362540622.SGD","IE0002141913.USD","IDNA","IE0002270589.USD","LU0058720904.USD","SGXZ57979304.SGD","LU1035775433.USD","LU2236285917.USD","IE00BZ9MQY76.HKD","SG9999013999.USD","LU1674673428.USD","LU2362541513.USD","LU2462157665.USD","LU0289739699.SGD","LU1430594728.SGD","IE00B19Z9P08.USD","BK4588","IBB","LU0889565916.HKD","VRTX","LU1674673691.USD","LU1093756168.USD","IE00B19Z3581.USD","LU1585245621.USD","LU2417539215.USD","LU1778281490.HKD","LU2324357040.USD","LU0417517546.SGD","LU0234570918.USD","IBBJ","LU2089984988.USD","BK4567","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793062?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，$福泰制药(VRTX)$(VRTX.US)早盘涨近7%，创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%，创记录新低。消息面上，SION表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁，但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病，会导致肺部进行性损伤。","market":"sh","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9P08.USD","LU0320765992.SGD","LU0058720904.USD","BIB","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU2462157665.USD","IBB","LU2236285917.USD","SG9999001176.SGD","GNMX","IBBQ","BK4567","IE00B19Z3B42.SGD","BK4139","LU1674673691.USD","SGXZ57979304.SGD","IE00B2B36J28.USD","IDNA","LU1674673428.USD","TBXU","IE0002141913.USD","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","LU0109394709.USD","LU2362541273.HKD","IE00B894F039.SGD","LU1430594728.SGD","IE00B19Z9Z06.USD","VRTX","IE00BFTCPJ56.SGD","LU0061475181.USD","LU2417539215.USD","LU2468319806.SGD","LU0079474960.USD","LU1778281490.HKD","LU0234570918.USD","BK4532","LU2362541513.USD","SG9999001176.USD","BBH","LU1093756168.USD","LU2456880835.USD","LU0256863811.USD","LU1585245621.USD","SG9999013999.USD","IE00B19Z3581.USD","PBE","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170275964","title":"异动解读｜福泰制药盘中上涨9.21%，Q2业绩超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1170275964","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170275964?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:30","pubTimestamp":1786368641,"startTime":"0","endTime":"0","summary":"8月10日，福泰制药盘中上涨9.21%，报540.08美元/股，成交额1.14亿美元。消息面上，公司近日发布Q2财报，营收33.3亿美元超市场预期的32.3亿美元，同比增长12.5%；调整后EPS为4.73美元，同比增长4.6%。同时公司上调全年营收指引至131亿至132亿美元，高于此前的129.5亿至131亿美元及市场预期的130.6亿美元。此外，百亿美元收购Crinetics交易预计本季度完成，将新增内分泌业务支柱，进一步拓宽公司管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180549438","title":"异动解读｜福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180549438","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180549438?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:08","pubTimestamp":1786360135,"startTime":"0","endTime":"0","summary":"8月10日，福泰制药盘前上涨3.26%，报515.0美元/股，成交额36.79万美元。消息面上，公司近日发布Q2财报，营收33.3亿美元超市场预期的32.3亿美元，同比增长12.5%；调整后EPS为4.73美元，同比增长4.6%。财报发布后，多家机构上调目标价：Cantor Fitzgerald上调至595美元，Rothschild上调至580美元，高盛此前已将目标价调升至652美元。此外，百亿美元收购Crinetics交易预计本季度完成，将新增内分泌业务支柱。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104230011","title":"异动解读｜福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1104230011","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104230011?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:14","pubTimestamp":1785852884,"startTime":"0","endTime":"0","summary":"8月4日，福泰制药盘中上涨3.05%，报481.47美元/股，成交额1.49亿美元。消息面上，公司公布第二季度业绩：调整后每股收益4.73美元，同比增长4.65%，符合市场预期；营收33.34亿美元，同比增长12.5%，超出分析师预期的32.32亿美元约1亿美元。更为关键的是，公司将全年营收指引从此前的129.5亿至131亿美元上调至131亿至132亿美元，高于FactSet一致预期的130.6亿美元。业绩公布后，Cantor Fitzgerald将目标价从590美元上调至595美元，维持增持评级。此前高盛亦将目标价上调至652美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 扩大领导团队，为下一阶段增长注入强劲动力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117517951?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王，2026年8月4日——全球间接税与合规领域的“决策到防御”先锋，Vertex Inc.，今日宣布其领导团队迎来三位新成员，旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入，将通过对人才、区域运营及技术创新的领导力扩展，进一步强化 Vertex 的全球增长战略。在 Vertex，她将负责全球人才与企业文化战略，构建起推动业务规模化发展所需的人才储备和组织能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013999.USD","LU0289739699.SGD","TISI","PBE","BK4023","IE0002270589.USD","IE00BZ9MQY76.HKD","IBB","GNMX","IE00B19Z9P08.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4588","BK4084","BK4099","LU1559883803.SGD","LU0079474960.USD","IE00B894F039.SGD","03160","BK4139","IBBQ","LU2237438978.USD","IE0009355771.USD","LU2089984988.USD","LU1430594728.SGD","LU0432979614.USD","TBXU","SGXZ57979304.SGD","LU0058720904.USD","LU2456880835.USD","BK4567","LU0757428866.USD","VERX","IE0002141913.USD","BK4120","LU2324357040.USD","BK4585","LU2362540622.SGD","LU1674673428.USD","LU0061475181.USD","LU0889565916.HKD","IE00B19Z3581.USD","LU1069344957.HKD","SG9999001176.SGD","LU2468319806.SGD","BBH","BK4533","LU0109394709.USD","IE00B19Z9Z06.USD","BK4555","LU2362541273.HKD","LU0823416689.USD","LU0234570918.USD","LU1093756325.SGD","LU2462157665.USD","LU2236285917.USD","LU1674673691.USD","LU1585245621.USD","LU0320765992.SGD","IDNA","BIB","IE00B4R5TH58.HKD","BK4234","LU2417539215.USD","SG9999001176.USD","BK4532","IE00BFTCPJ56.SGD","LU1093756168.USD","TM","LU0566484027.USD","LU1035775433.USD","LU0256863811.USD","LU0417517546.SGD","PW","VRTX","LU1778281490.HKD","IE00BJT1NW94.SGD","BK4604","LU2362541513.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539622","title":"非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元，Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539622?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:59","pubTimestamp":1785833974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIB","KCE","IE00B4R5TH58.HKD","BK4585","BK4139","IE00BFTCPJ56.SGD","LU1778281490.HKD","BK4127","LU1585245621.USD","LTGO","BBH","LU0058720904.USD","GNMX","IDNA","IE00B19Z3581.USD","LU0256863811.USD","IE0002141913.USD","LU2468319806.SGD","BK4588","FRHC","REDS","LU1093756168.USD","LU2456880835.USD","IE00B19Z3B42.SGD","IPOS","LU0823416689.USD","PBE","IE00BZ9MQY76.HKD","BK4532","LU1430594728.SGD","LU0889565916.HKD","TBXU","LU2324357040.USD","LU2362541513.USD","LU0289739699.SGD","IE00B19Z9Z06.USD","LU0417517546.SGD","LU1093756325.SGD","SG9999013999.USD","BK4533","IBB","IBBQ","IE00B19Z9P08.USD","LU2362541273.HKD","LU0234570918.USD","VRTX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1674673428.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126575276","title":"福泰制药重申2026年全年指引：GAAP与非GAAP研发、AI研发及销售管理费用预期不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126575276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126575276?lang=zh_cn&edition=full","pubTime":"2026-08-04 04:07","pubTimestamp":1785787669,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）再次确认其2026年全年财务指引。在涵盖GAAP及非GAAP口径下的研发支出、AI研发投入以及销售、一般及管理费用（SG&A）方面，该公司均维持此前预期不变，未作出任何调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","IBB","LU1093756325.SGD","LU2362541513.USD","SG9999001176.SGD","TBXU","LU1430594728.SGD","IE00B19Z9P08.USD","LU1674673428.USD","SGXZ57979304.SGD","LU2362540622.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","LU2456880835.USD","BIB","IE00B4R5TH58.HKD","IE0009355771.USD","BK4532","LU0432979614.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU2362541273.HKD","IE00B19Z3B42.SGD","BBH","LU0234570918.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","SG9999013999.USD","PBE","VRTX","BK4585","LU0256863811.USD","GNMX","LU0058720904.USD","IBBQ","BK4533","LU0061475181.USD","LU2462157665.USD","LU0079474960.USD","IE00B19Z9Z06.USD","LU2237438978.USD","BK4139","IE00B894F039.SGD","IE0002270589.USD","LU2324357040.USD","BK4588","LU0823416689.USD","SG9999001176.USD","BK4567","LU1674673691.USD","IDNA","LU2236285917.USD","LU1585245621.USD","LU1035775433.USD","LU0109394709.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU2417539215.USD","LU1069344957.HKD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0256863811.USD","BK4585","LU0109394709.USD","LU1674673428.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU0432979614.USD","LU0889565916.HKD","LU1069344957.HKD","LU2456880835.USD","SG9999001176.SGD","LU0320765992.SGD","LU1430594728.SGD","VRTX","IE00B2B36J28.USD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","IBB","IE00B19Z9Z06.USD","LU1674673691.USD","LU0079474960.USD","LU1585245621.USD","BK4121","LU2236285917.USD","LU0234570918.USD","BK4532","LU2462157665.USD","BK4533","LU2237438978.USD","IE0002270589.USD","ABCL","LU0058720904.USD","LU0823416689.USD","LU2417539215.USD","SG9999013999.USD","BBH","IE00B894F039.SGD","LU1035775433.USD","IE00B19Z9P08.USD","LU2362540622.SGD","IE00B19Z3581.USD","LU2362541273.HKD","LU2324357040.USD","TBXU","IE0002141913.USD","BK4567","BIB","LU0417517546.SGD","BK4588","LU1778281490.HKD","IDNA","LU1093756168.USD","SG9999001176.USD","BK4535","LU0061475181.USD","IE00BJJMRZ35.SGD","LU2362541513.USD","PBE","IBBQ","GNMX","LU0289739699.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147206442?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU0061475181.USD","LU1069344957.HKD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU0109394709.USD","BK4585","IBBQ","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0079474960.USD","IE00B4R5TH58.HKD","LU0256863811.USD","BK4588","BBH","IE00B19Z9Z06.USD","IDNA","IE00B894F039.SGD","TBXU","BK4533","LU2236285917.USD","LU2237438978.USD","GNMX","LU1674673428.USD","LU0823416689.USD","SG9999001176.USD","LU0432979614.USD","LU1778281490.HKD","BK4139","IE0009355771.USD","IE00BJT1NW94.SGD","LU0234570918.USD","LU0289739699.SGD","ABCL","BK4535","LU0320765992.SGD","LU1093756325.SGD","LU1430594728.SGD","LU1585245621.USD","LU1674673691.USD","LU2417539215.USD","IBB","BIB","SG9999013999.USD","LU2362541513.USD","BK4532","LU2362541273.HKD","BK4121","IE00B19Z3581.USD","LU2324357040.USD","LU0058720904.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU2362540622.SGD","PBE","IE00B2B36J28.USD","LU2462157665.USD","VRTX","IE00BJJMRZ35.SGD","SG9999001176.SGD","BK4567","IE00B19Z9P08.USD","LU1035775433.USD","LU1093756168.USD","LU2456880835.USD","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180578857","title":"财报前瞻｜福泰制药本季度营收预计增11.23%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1180578857","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180578857?lang=zh_cn&edition=full","pubTime":"2026-07-27 08:08","pubTimestamp":1785110926,"startTime":"0","endTime":"0","summary":"福泰制药将于2026年08月03日发布季度财报，市场关注营收增长与并购后的利润表现。上季度营收29.87亿美元，同比增长7.82%；毛利率54.66%；归母净利润10.31亿美元，同比增长59.59%；净利率34.53%；调整后每股收益4.47美元，同比增长10.10%。本季度利润率端，若渠道与市场推广投入保持有序，可在维持处方增长的同时避免对毛利率产生过大扰动，结合上季度54.66%的毛利率基础，关注单位经济的微调空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜福泰制药本季度营收预计增11.23%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117599","title":"Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117599","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651117599?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:10","pubTimestamp":1783951848,"startTime":"0","endTime":"0","summary":"金吾财讯 | Vertex Pharmaceuticals  与 Crinetics Pharmaceuticals  共同披露收购协议，企业将以每股 85 美元现金完成标的全额收购，交易对应 Crinetics 整体股权价值约 100 亿美元，扣除标的账面现金后净交易对价 88 亿美元，交易预计 2026 年第三季度完成，消息落地后 Crinetics 盘后股价实现翻倍上涨。Vertex 计划依托自有现金搭配债务工具完成交易资金筹措，美国银行、摩根士丹利提供 45 亿美元全额过渡性融资，收购落地后企业罕见病内分泌赛道产品矩阵将实现大幅扩容。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","BIB","VERX","LU0109394709.USD","LU1674673428.USD","LU0256863811.USD","LU2362541273.HKD","LU2462157665.USD","PBE","LU2362540622.SGD","SG9999001176.USD","BK4007","BK4585","LU2417539215.USD","IBBQ","LU1069344957.HKD","BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BZ9MQY76.HKD","IE0002270589.USD","VRTX","LU1093756325.SGD","LU0079474960.USD","CRNX","SG9999001176.SGD","LU0889565916.HKD","LU2237438978.USD","LU0757428866.USD","LU1093756168.USD","LU0234570918.USD","IE0009355771.USD","IE00B19Z3581.USD","BK4532","LU1585245621.USD","LU0566484027.USD","IE00BFTCPJ56.SGD","BBH","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0061475181.USD","IBB","IDNA","LU0432979614.USD","LU1778281490.HKD","LU2456880835.USD","LU1035775433.USD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650760159","title":"福泰制药百亿美元并购透露了什么讯号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650760159","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650760159?lang=zh_cn&edition=full","pubTime":"2026-07-11 22:55","pubTimestamp":1783781749,"startTime":"0","endTime":"0","summary":"01百亿美元级现金并购的底气福泰制药2025年全年营收120.01亿美元，同比增长9%，非GAAP净利润47.5亿美元，毛利率维持85%以上高位，账面现金及有价证券超过123亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783569458583958068","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0823416689.USD","LU0289739699.SGD","LU2324357040.USD","BIB","BBH","IE00B894F039.SGD","LU0079474960.USD","SG9999001176.SGD","VRTX","LU1093756168.USD","LU1585245621.USD","LU0320765992.SGD","KCE","IE00BJT1NW94.SGD","LU2417539215.USD","LU1778281490.HKD","LU1069344957.HKD","LU2362540622.SGD","SG9999001176.USD","LU0234570918.USD","BK4567","LU0061475181.USD","LU2236285917.USD","IE0002141913.USD","BK4139","LU1093756325.SGD","BK4532","IE00B19Z3581.USD","LU1035775433.USD","IBB","IE00BFTCPJ56.SGD","MYLD","SGXZ57979304.SGD","PBE","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4588","IE00B2B36J28.USD","LU2462157665.USD","IE00BZ9MQY76.HKD","IE0009355771.USD","IE00B4R5TH58.HKD","IE0002270589.USD","CALF","LU0058720904.USD","IE00BJJMRZ35.SGD","XMMO","IDNA","LU0109394709.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157031563","title":"异动解读｜福泰制药盘中下跌3.24%，百亿美元收购Crinetics引发市场消化压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1157031563","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157031563?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:37","pubTimestamp":1783532262,"startTime":"0","endTime":"0","summary":"7月8日，福泰制药盘中下跌3.24%，报505.32美元/股，成交额4.09亿美元。消息面上，福泰制药于7月7日宣布将以每股85美元现金收购Crinetics Pharmaceuticals，交易总股权价值约100亿美元，较后者收盘价溢价102%，为公司史上最大规模收购。福泰制药预计收购将于第三季度完成，2029年方可对调整后营业利润产生正贡献。此前交易公布当日福泰制药已跌超2%，当前跌幅为市场对收购成本及整合风险的进一步定价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299398","title":"大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299398","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649299398?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512080,"startTime":"0","endTime":"0","summary":"摩根士丹利发布研报，对福泰制药以100亿美元收购Crinetics的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。值得注意的是，摩根士丹利担任福泰制药的财务顾问，协助该公司达成收购Crinetics的协议。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464871.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2237438978.USD","IE00B894F039.SGD","LU0053666078.USD","LU0098860793.USD","LU0390134368.USD","BBH","LU1363072403.SGD","LU0823416689.USD","IBB","LU1674673691.USD","LU0267386448.USD","LU0528227936.USD","LU2487616109.SGD","LU0058720904.USD","IAI","IBBQ","LU1732799900.SGD","IE0002270589.USD","LU2111349929.HKD","LU2236285917.USD","KBWB","LU2133065610.SGD","LU2362541273.HKD","IE00B19Z9P08.USD","LU2456880835.USD","LU1791710400.SGD","BK4139","PBE","LU1720051017.SGD","IE00B19Z3581.USD","IE0009355771.USD","IE0002141913.USD","LU1585245621.USD","VRTX","BK4533","LU0109394709.USD","LU1720051108.HKD","LU2362540622.SGD","IE00BZ9MQY76.HKD","IDNA","LU0882574139.USD","LU0432979614.USD","LU2089284900.SGD","BK4581","SG9999001176.USD","BIB","LU0210528500.USD","LU0079474960.USD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939579","title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939579","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649939579?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:40","pubTimestamp":1783510856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1244550577.SGD","IBB","BK4127","SG9999001176.SGD","LU1430594728.SGD","LU1674673428.USD","IAI","KBWB","LU2362540622.SGD","IE00BJJMRZ35.SGD","LU0882574139.USD","LU0053666078.USD","LU0267386448.USD","LU0314104364.USD","BIB","LU1668664300.SGD","IE00B19Z3B42.SGD","BBH","LU0795875086.SGD","LU0417517546.SGD","SG9999013999.USD","LU1074936037.SGD","PBE","VRTX","LU2347655156.SGD","LU0058720904.USD","IBBQ","LU0061475181.USD","LU2133065610.SGD","LU1244550221.USD","LU2462157665.USD","LU0079474960.USD","IE00B19Z9Z06.USD","LU2237438978.USD","BK4139","LU1548497426.USD","LU2271345857.HKD","LU0795875169.SGD","LU2089283258.USD","LU0823416689.USD","SG9999001176.USD","BK4567","IDNA","LU2487616109.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2417539215.USD","LU1720051017.SGD","LU2362541273.HKD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969921","title":"RBC Capital上调福泰制药目标价至570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969921","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649969921?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:24","pubTimestamp":1783499090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0708994859.HKD","IE00B2B36J28.USD","SGXZ57979304.SGD","BK4139","LU0058720904.USD","SG9999013999.USD","PBE","LU2362540622.SGD","VRTX","BBH","LU0310800379.SGD","BK4585","LU2324357040.USD","LU0289739699.SGD","IDNA","LU0128525929.USD","LU1093756325.SGD","UDN","LU2462157665.USD","SG9999001176.USD","RY","IE00B19Z3B42.SGD","IE0009355771.USD","IBB","LU0320765992.SGD","LU2237438978.USD","IE00BJJMRZ35.SGD","BK4533","BIB","LU0417517546.SGD","UUP","IE00B19Z9P08.USD","IE00B894F039.SGD","LU1069344957.HKD","LU2456880835.USD","BK4207","LU0234570918.USD","LU1778281490.HKD","LU0823416689.USD","LU2417539215.USD","IE00B4R5TH58.HKD","IBBQ","LU1093756168.USD","BK4532","BK4567","IE00BFTCPJ56.SGD","LU0029864427.USD","IE00B19Z9Z06.USD","LU1267930573.SGD","GSIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111378876","title":"Vera Therapeutics股价飙升：肾病新药获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1111378876","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111378876?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:47","pubTimestamp":1783450047,"startTime":"0","endTime":"0","summary":"周二，Vera Therapeutics, Inc.的股价上涨约8%，此前美国食品药品监督管理局批准了其用于治疗IgA肾病的药物。这款名为Trutakna的药物通过阻断两种蛋白质来发挥作用，这两种蛋白质会促使免疫系统产生抗体，这些抗体在肾脏中积聚并造成损伤。这是美国首个获批同时靶向这两种蛋白质的药物，尽管已有其他几种药物治疗该疾病。福泰制药正在研发一种同样能阻断这两种蛋白质的类似药物，FDA预计将在今年晚些时候对此做出裁决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","IE0002141913.USD","BK4567","PBE","LU1674673428.USD","LU1585245621.USD","IE00B894F039.SGD","IBBQ","IE00B19Z9P08.USD","IBB","LU0058720904.USD","IE00B4R5TH58.HKD","LU0061475181.USD","LU2324357040.USD","LU2362541273.HKD","LU2462157665.USD","SGXZ57979304.SGD","BK4585","IE00B19Z3B42.SGD","LU0079474960.USD","LU0289739699.SGD","LU0417517546.SGD","IE0002270589.USD","LU2236285917.USD","LU0432979614.USD","LU1778281490.HKD","VERA","BK4139","LU1069344957.HKD","LABU","LU0889565916.HKD","IE0009355771.USD","VRTX","BBH","LU1674673691.USD","SG9999013999.USD","IDNA","SG9999001176.USD","SG9999001176.SGD","IE00BFTCPJ56.SGD","BK4532","LU2417539215.USD","LU2456880835.USD","BK4539","BK4533","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU1430594728.SGD","LU1035775433.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4588","IE00BZ9MQY76.HKD","LU1093756168.USD","LU2362541513.USD","LU0256863811.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","LU0234570918.USD","BIB","LU0823416689.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vrtx.com","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.1413},{"period":"3month","weight":0.281},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.3926},{"period":"ytd","weight":0.2011}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立，是一家全球性的生物技术公司，致力于科学创新，旨在为患有严重疾病的个人，特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。","yearOnYearQuotes":[{"month":1,"riseRate":0.657143,"avgChangeRate":0.034393},{"month":2,"riseRate":0.457143,"avgChangeRate":0.001601},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021959},{"month":4,"riseRate":0.6,"avgChangeRate":0.01636},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076942},{"month":6,"riseRate":0.571429,"avgChangeRate":0.030748},{"month":7,"riseRate":0.457143,"avgChangeRate":-0.005619},{"month":8,"riseRate":0.638889,"avgChangeRate":0.048963},{"month":9,"riseRate":0.485714,"avgChangeRate":0.030192},{"month":10,"riseRate":0.542857,"avgChangeRate":0.000856},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.02026},{"month":12,"riseRate":0.657143,"avgChangeRate":0.071588}],"exchange":"NASDAQ","name":"福泰制药","nameEN":"Vertex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福泰制药,VRTX,福泰制药股票,福泰制药股票老虎,福泰制药股票老虎国际,福泰制药行情,福泰制药股票行情,福泰制药股价,福泰制药股市,福泰制药股票价格,福泰制药股票交易,福泰制药股票购买,福泰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}